# INTRODUCING THE SYN-ONE TEST™ TO HELP DIAGNOSE DEMENTIA WITH LEWY BODIES

A convenient, evidence-based tool to support physicians and patients

Making a definitive diagnosis of dementia with Lewy bodies (DLB) can be complicated. Patient history, symptoms, and other data may lead to an erroneous diagnosis of Alzheimer's disease and result in adverse treatment paths.

That's why the founders of CND Life Sciences embarked on a mission to prove that pathologic evidence of phosphorylated synuclein (p-syn) can be reliably detected in cutaneous nerve fibers of patients with DLB.

By analyzing three (3) small skin punch biopsies taken in your office, CND detects, visualizes, and quantifies the presence of p-syn in cutaneous nerve fibers--providing you with objective evidence to support a diagnosis and overall treatment plan.

**Diagnose DLB with increased clarity and confidence**

## CLINICAL USE CASE EXAMPLES FOR DLB

- If you have a patient with a dementia who does not fit cleanly into an AD or fronto-temporal dementia phenotype
- If you suspect DLB, but the patient does not have immediate access to a movement or cognitive disorder specialist who can confirm the diagnosis
- If you have a patient with significant autonomic failure with some subtle cognitive problems

## SYN-ONE TEST ADVANTAGES:

- High sensitivity and specificity for synucleinopathy
- Minimally invasive
- Provides visual proof of p-syn
- Uses anatomical pathology codes covered by Medicare
- Convenient and simple
- Supports shared decision-making with patients

**To learn more and order the free Syn-One Test Biopsy Kit, visit cndlifesciences.com.**

CND Life Sciences™
Diagnostic Insights for Life